Bionomics BNC210 Expansion into Social Anxiety Disorder
- Rapid oral absorption of BNC210 novel tablet formulation ideally suited for acute treatment of anxiety in patients with Social Anxiety Disorder
- BNC210 Phase 2b PTSD trial on target for start in mid-2021 with U.S. CRO Premier Research selected and clinical site identification underway
- Pipeline expansion puts Company on path for two Phase 2 programs...
Read more: Bionomics BNC210 Expansion into Social Anxiety Disorder